IMMUNE MODULATION OF THE PERITONEAL OVARIAN TUMOR MICROENVIRONMENT USING BOTH NOVEL AND STANDARD OF CARE THERAPIES

Henning De May, University of New Mexico

Abstract

Tumor immunotherapy has revolutionized the treatment paradigm of several malignancies, including lung cancer and melanoma. Despite significant evidence that ovarian cancer is an immunologically regulated disease, the advances in immunotherapy have not translated to improved clinical outcomes. This is thought to be secondary to the highly immune-suppressive nature of the peritoneal microenvironment. Novel interventions and paired therapies are demonstrating success in the pre-clinical setting. Here we describe the immunological and anti-tumor effects of novel and standard of care therapies for the treatment of ovarian cancer using syngeneic murine models of high grade epithelial ovarian cancer.